现在位置 >首页 > 时讯速递
0℃
Research Letter April 10, 2020 Seasonal Influenza Activity During the SARS-CoV-2 Outbreak in Japan Haruka Sakamoto, Masahiro Ishikane, Peter Ueda JAMA. Published online April 10, 2020. doi:10.1001/jama.2020.6173 Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak began, measures for avoiding disease transmission have been widely promoted in Japan, such as use of masks and handwashing, remote work, and cancellation of ...
阅读全文
0℃
Feature Global Health Covid-19: Why Germany’s case fatality rate seems so low Ned Stafford BMJ 2020; 369:m1395 doi: https://doi.org/10.1136/bmj.m1395 Germany has the third highest number of coronavirus cases in Europe, but deaths are relatively few when compared with neighbouring countries. Ned Stafford explains why As the covid-19 pandemic continues to grow in severity, one of the most closely watched statistics has been Germany’s number of ...
阅读全文
0℃
Research Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Tao Chen, Di Wu, Huilong Chen, et al BMJ 2020; 368:m1091 doi: https://doi.org/10.1136/bmj.m1091 Abstract Objective To delineate the clinical characteristics of patients with coronavirus disease 2019 (covid-19) who died. Design Retrospective case series. Setting Tongji Hospital in Wuhan, China. Participants Among a cohort of 799 ...
阅读全文
0℃
Research Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study Shufa Zheng, Jian Fan, Fei Yu, et al BMJ 2020; 369: m1443 doi: https://doi.org/10.1136/bmj.m1443 (Published 21 April 2020) Abstract Objective To evaluate viral loads at different stages of disease progression in patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SA...
阅读全文
0℃
News Covid-19: First coronavirus was described in The BMJ in 1965 Elisabeth Mahase BMJ 2020; 369: m1547 doi: https://doi.org/10.1136/bmj.m1547 (Published 16 April 2020) The first description of human coronavirus—a family of viruses that now includes SARS-CoV-2, the cause of the current covid-19 pandemic—was published in The BMJ in 1965. The research, led by virologist David Tyrrell at the Common Cold Unit in Wiltshire, England, involved ...
阅读全文
0℃
Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial Elodie von Dach, Werner C. Albrich, Anne-Sophie Brunel, et al JAMA. 2020;323(21):2160-2169. doi:10.1001/jama.2020.6348 Abstract Importance Antibiotic overuse drives antibiotic resistance. Gram-negative bacteremia is a common infection that ...
阅读全文
0℃
An Illustrated Guide to the Chest CT in COVID-19 Mar 16 2020 Jon-Emile S. Kenny MD [@heart_lung] with illustrations by Carla M. Canepa MD [@_carlemd_] Background   The coronavirus moniker originates from the appearance of the virus under the electron microscope – protein peplomers radiating from the viral envelope like a crown.  Prior to 2019, there were 6 known human-infecting coronaviruses, four of which caused only mild respiratory ...
阅读全文
0℃
ARTICLES| VOLUME 395, ISSUE 10238, P1715-1725, MAY 30, 2020 Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study Amitava Banerjee, Laura Pasea, Steve Harris, et al Lancet 2020; 395: 1715-1725 Summary Background The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Pre...
阅读全文
0℃
0℃
ORIGINAL ARTICLE Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Jason D. Goldman, David C.B. Lye, David S. Hui, et al N Engl J Med May 27, 2020DOI: 10.1056/NEJMoa2015301 Abstract BACKGROUND Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS We conducted a randomized, open-label, phase 3 trial involving hospitalized patients wit...
阅读全文
×
腾讯微博